[go: up one dir, main page]

BR112022000004A2 - Peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos - Google Patents

Peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos

Info

Publication number
BR112022000004A2
BR112022000004A2 BR112022000004A BR112022000004A BR112022000004A2 BR 112022000004 A2 BR112022000004 A2 BR 112022000004A2 BR 112022000004 A BR112022000004 A BR 112022000004A BR 112022000004 A BR112022000004 A BR 112022000004A BR 112022000004 A2 BR112022000004 A2 BR 112022000004A2
Authority
BR
Brazil
Prior art keywords
bcl9
mimetic peptides
methods
kit
composition
Prior art date
Application number
BR112022000004A
Other languages
English (en)
Inventor
Jay Kappel Barry
E Gallagher Erin
Gene Merutka
Andrew Rotolo Jimmy
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of BR112022000004A2 publication Critical patent/BR112022000004A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos. trata-se de peptídeos miméticos bcl9 que têm uma região de domínio 2 de homologia a-helicoidal (hd2) modificada e, opcionalmente, uma região de penetração celular, composições que compreendem os peptídeos miméticos bcl9 e métodos para inibir a proliferação e/ou promover a citotoxicidade em uma célula neoplásica com o uso dos peptídeos miméticos bcl9.
BR112022000004A 2019-07-05 2020-07-06 Peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos BR112022000004A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870938P 2019-07-05 2019-07-05
PCT/US2020/040889 WO2021007158A1 (en) 2019-07-05 2020-07-06 Modified bcl9 mimetic peptides

Publications (1)

Publication Number Publication Date
BR112022000004A2 true BR112022000004A2 (pt) 2022-03-22

Family

ID=74114087

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000004A BR112022000004A2 (pt) 2019-07-05 2020-07-06 Peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos

Country Status (11)

Country Link
US (1) US20220275036A1 (pt)
EP (1) EP3994160A4 (pt)
JP (2) JP7663249B2 (pt)
KR (1) KR20220030992A (pt)
CN (1) CN114144424A (pt)
AU (1) AU2020311873B2 (pt)
BR (1) BR112022000004A2 (pt)
CA (1) CA3144458A1 (pt)
IL (1) IL289460A (pt)
MX (1) MX2022000283A (pt)
WO (1) WO2021007158A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024216237A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
CN119709745A (zh) * 2024-12-17 2025-03-28 暨南大学附属第一医院（广州华侨医院） 抑制BCL-9的shRNA、重组病毒载体在治疗视网膜血管新生相关疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715366A1 (en) 2011-04-15 2020-09-30 Dana Farber Cancer Institute, Inc. Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
CA3000866A1 (en) 2015-10-05 2017-04-13 Wntrx Pharmaceuticals Inc. Stabilized bcl9 peptides for treatment of aberrant wnt signaling
CN111836632A (zh) 2017-11-09 2020-10-27 温特瑞克斯制药有限公司 Bcl9肽和其变体
EP4021473A4 (en) * 2019-08-30 2023-10-11 Ohio State Innovation Foundation STAPLED BETA-CATENIN LIGANDS

Also Published As

Publication number Publication date
EP3994160A1 (en) 2022-05-11
US20220275036A1 (en) 2022-09-01
MX2022000283A (es) 2022-09-23
KR20220030992A (ko) 2022-03-11
JP2025102864A (ja) 2025-07-08
AU2020311873A1 (en) 2022-01-27
NZ783678A (en) 2024-08-30
EP3994160A4 (en) 2023-08-02
JP7663249B2 (ja) 2025-04-16
JP2022538686A (ja) 2022-09-05
AU2020311873B2 (en) 2024-03-21
WO2021007158A1 (en) 2021-01-14
CA3144458A1 (en) 2021-01-14
CN114144424A (zh) 2022-03-04
IL289460A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112022000004A2 (pt) Peptídeos miméticos bcl9, composição, kit, molécula de ácido nucleico e métodos
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
MY204607A (en) Bitumen compositions comprising lignin
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
BR112022016220A2 (pt) Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
PH12019500596B1 (en) Recombinant binding proteins and their use
EA202192796A1 (ru) Tigit и pd-1/tigit-связывающие молекулы
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201001628A1 (ru) Модифицированные полипептиды фактора vii и их применение
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112013006331A2 (pt) composições de fulvestranto e métodos de uso
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
EA202092748A1 (ru) Модуляторы экспрессии apol1
BR112022004563A2 (pt) Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer
ZA202006077B (en) Human kynureninase enzymes and uses thereof
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
BR112021017703A8 (pt) Receptores de células t wt1 de alta avidez e usos dos mesmos
BR112019003950A2 (pt) identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SAPIENCE THERAPEUTICS, INC. (US)